| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Hepion Pharmaceuticals, Inc. (HEPA) has 0 insiders with recent SEC Form 4 filings, including 14 buys and 0 sells. HEPA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 27, 2023 | Wijngaard Peter | Director | Buy | 5,000 | $3.07 | $15,350.00 | +43.5% | |
| Sep 19, 2023 | Wijngaard Peter | Director | Buy | 3,000 | $5.61 | $16,841.12 | +29.6% | |
| Sep 18, 2023 | Foster Robert T | CEO And Director | Buy | 1,600 | $5.60 | $8,960.00 | +3.3% | |
| Sep 15, 2023 | Foster Robert T | CEO,CSO And Director | Buy | 1,600 | $5.40 | $8,640.00 | +3.4% | |
| Feb 18, 2021 | Foster Robert T | CEO And Director | Buy | 20,000 | $2.00 | $40,000.00 | +79.2% | |
| Feb 18, 2021 | Cavan John T | Chief Financial Officer | Buy | 10,000 | $2.00 | $20,000.00 | +208.3% | |
| Feb 16, 2021 | Wijngaard Peter | Director | Buy | 10,000 | $2.20 | $22,000.00 | +50.0% | |
| Dec 18, 2020 | Wijngaard Peter | Director | Buy | 20,000 | $1.91 | $38,200.00 | New | |
| Dec 8, 2020 | Foster Robert T | CEO And Director | Buy | 25,000 | $1.58 | $39,417.50 | +9,653% | |
| Dec 2, 2020 | Brancaccio John P | Director | Buy | 7,000 | $1.53 | $10,710.00 | +87,500% |